Response to: 'Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis' by Scheicht
- PMID: 35168945
- DOI: 10.1136/annrheumdis-2020-217063
Response to: 'Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis' by Scheicht
Keywords: autoimmune diseases; methotrexate; systemic vasculitis.
Conflict of interest statement
Competing interests: CM was the convenor of the 2016 EULAR recommendations for the management of ANCA-associated vasculitis. BH is the convenor of the 2022 EULAR recommendations for the management of ANCA-associated vasculitis.
Comment on
-
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23. Ann Rheum Dis. 2016. PMID: 27338776
-
Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Ann Rheum Dis. 2022 Jun;81(6):e89. doi: 10.1136/annrheumdis-2020-217041. Epub 2020 Feb 5. Ann Rheum Dis. 2022. PMID: 32024649 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
